Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review
Authors
Keywords
-
Journal
CNS DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-02
DOI
10.1007/s40263-020-00734-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE
- (2019) Jai Perumal et al. BMC Neurology
- Effect of dalfampridine on information processing speed impairment in multiple sclerosis
- (2019) Laura De Giglio et al. NEUROLOGY
- Money Management in Multiple Sclerosis: The Role of Cognitive, Motor, and Affective Factors
- (2019) Goverover Yael et al. Frontiers in Neurology
- Ending Reliance on Statistical Significance Will Improve Environmental Inference and Communication
- (2019) Eric P. Smith Estuaries and Coasts
- Consequences of relying on statistical significance: Some illustrations
- (2018) Ben Van Calster et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years
- (2018) Sarah D. Broicher et al. JOURNAL OF NEUROLOGY
- Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study
- (2018) C. Bakirtzis et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Dalfampridine benefits ambulation but not cognition in multiple sclerosis
- (2018) Nikhil Satchidanand et al. Multiple Sclerosis Journal
- Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.
- (2018) C. Arreola-Mora et al. Multiple Sclerosis and Related Disorders
- Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
- (2017) Giancarlo Comi et al. JOURNAL OF NEUROLOGY
- Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial
- (2017) Dennis Chan et al. LANCET NEUROLOGY
- Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
- (2017) Ralph HB Benedict et al. Multiple Sclerosis Journal
- Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
- (2017) Ralph HB Benedict et al. Multiple Sclerosis Journal
- Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
- (2017) Ralph HB Benedict et al. Multiple Sclerosis Journal
- Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
- (2017) Ralph HB Benedict et al. Multiple Sclerosis Journal
- Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study
- (2017) Patricia K. Coyle et al. Multiple Sclerosis and Related Disorders
- The ASA's Statement onp-Values: Context, Process, and Purpose
- (2016) Ronald L. Wasserstein et al. AMERICAN STATISTICIAN
- Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER
- (2016) Elizabeth W. Triche et al. CLINICAL NEUROPHARMACOLOGY
- Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial
- (2016) Laura De Giglio et al. CNS DRUGS
- Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis
- (2016) Shumita Roy et al. CNS DRUGS
- Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients
- (2016) Pietro Iaffaldano et al. JOURNAL OF NEUROLOGY
- QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients
- (2016) Tjalf Ziemssen et al. JOURNAL OF NEUROLOGY
- Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study
- (2016) Laure Peyro Saint Paul et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study)
- (2016) Roberta Lanzillo et al. Multiple Sclerosis Journal
- Information processing speed in multiple sclerosis: Past, present, and future
- (2016) Silvana L Costa et al. Multiple Sclerosis Journal
- High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
- (2016) Karen Schreiber et al. Multiple Sclerosis Journal
- The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
- (2016) Ludwig Kappos et al. NEUROLOGY
- No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study)
- (2016) Roberta Lanzillo et al. Multiple Sclerosis Journal
- Information processing speed in multiple sclerosis: Past, present, and future
- (2016) Silvana L Costa et al. Multiple Sclerosis Journal
- High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
- (2016) Karen Schreiber et al. Multiple Sclerosis Journal
- Dalfampridine effects on cognition, fatigue, and dexterity
- (2016) Melanie Korsen et al. Brain and Behavior
- Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study
- (2016) M. Sundgren et al. Multiple Sclerosis and Related Disorders
- Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
- (2015) Tjalf Ziemssen et al. BMC Neurology
- Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients
- (2015) Katja Pavsic et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Verbal Fluencies and Fampridine Treatment in Multiple Sclerosis
- (2015) Eloi Magnin et al. EUROPEAN NEUROLOGY
- Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
- (2015) Ludwig Kappos et al. JOURNAL OF NEUROLOGY
- Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis
- (2015) Lenka Novakova et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Effects of single dose mixed amphetamine salts - extended release on processing speed in multiple sclerosis: a double blind placebo controlled study
- (2015) Sarah A. Morrow et al. PSYCHOPHARMACOLOGY
- Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings
- (2015) Flavia Mattioli et al. PLoS One
- Effects of Rivastigmine on Memory and Cognition in Multiple Sclerosis
- (2014) Vahid Shaygannejad et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
- (2014) Tjalf Ziemssen et al. JOURNAL OF NEUROLOGY
- Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial
- (2014) Naghmeh Mokhber et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment
- (2014) HB Jensen et al. Multiple Sclerosis Journal
- The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis
- (2013) Pietro Iaffaldano et al. BRAIN BEHAVIOR AND IMMUNITY
- A Randomized Controlled Pilot Trial: The Effects of EGb 761 on Information Processing and Executive Function in Multiple Sclerosis
- (2013) Bruce J. Diamond et al. Explore-The Journal of Science and Healing
- Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
- (2013) G. Edan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Long-term effects of dalfampridine in patients with multiple sclerosis
- (2013) T. Ruck et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study
- (2013) Maureen Lacy et al. Multiple Sclerosis Journal
- Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study
- (2013) Francesco Patti et al. PLoS One
- Impact of Armodafinil on Cognition in Multiple Sclerosis
- (2012) Jared Bruce et al. Cognitive and Behavioral Neurology
- Cognitive Impairment in Multiple Sclerosis
- (2012) Jesus Lovera et al. Current Neurology and Neuroscience Reports
- Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
- (2012) C. Lang et al. EUROPEAN NEUROLOGY
- Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study
- (2012) Sarah A. Morrow et al. JOURNAL OF NEUROLOGY
- Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients
- (2012) M Mäurer et al. Multiple Sclerosis Journal
- Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
- (2012) Iris-Katharina Penner et al. Multiple Sclerosis Journal
- Ginkgo biloba does not improve cognitive function in MS: A randomized placebo-controlled trial
- (2012) J. F. Lovera et al. NEUROLOGY
- Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study
- (2012) Pietro Iaffaldano et al. PLoS One
- Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis
- (2011) Carmen Tur ARCHIVES OF NEUROLOGY
- Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: A pilot analysis
- (2011) Alexandra Schröder et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Cognition in multiple sclerosis
- (2011) Dawn W Langdon CURRENT OPINION IN NEUROLOGY
- A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis
- (2011) E. J. Fox et al. EUROPEAN JOURNAL OF NEUROLOGY
- Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS
- (2011) Bianca Weinstock-Guttman et al. JOURNAL OF NEUROLOGY
- HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis
- (2011) F Möller et al. Multiple Sclerosis Journal
- Unemployment in multiple sclerosis: the contribution of personality and disease
- (2011) Lauren B Strober et al. Multiple Sclerosis Journal
- L-amphetamine improves memory in MS patients with objective memory impairment
- (2011) James F Sumowski et al. Multiple Sclerosis Journal
- The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue
- (2011) S Huolman et al. Multiple Sclerosis Journal
- Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
- (2011) DW Langdon et al. Multiple Sclerosis Journal
- Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis
- (2011) L. B. Krupp et al. NEUROLOGY
- Fatigue and Cognition in Patients with Relapsing Multiple Sclerosis Treated with Interferon Beta
- (2010) Maria Melanson et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial
- (2010) JF Lovera et al. Multiple Sclerosis Journal
- Assessing changes in relapse rates in multiple sclerosis
- (2010) Seidu Inusah et al. Multiple Sclerosis Journal
- Natalizumab efficacy on cognitive impairment in MS
- (2010) F. Mattioli et al. NEUROLOGICAL SCIENCES
- The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study
- (2010) Flavia Mattioli et al. NEUROLOGICAL SCIENCES
- Modafinil effects in multiple sclerosis patients with fatigue
- (2009) Rüdiger Lange et al. JOURNAL OF NEUROLOGY
- The effects of l-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial
- (2009) Sarah A. Morrow et al. JOURNAL OF NEUROLOGY
- Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis
- (2009) F. Patti et al. Multiple Sclerosis Journal
- A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
- (2009) X. Montalban et al. Multiple Sclerosis Journal
- Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients
- (2008) R. H. B. Benedict et al. JOURNAL OF NEUROLOGY
- Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis
- (2008) S Cader et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process
- (2008) Yermi Harel et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Cognitive impairment in multiple sclerosis
- (2008) Nancy D Chiaravalloti et al. LANCET NEUROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started